ArticleJournal of virology2002
Sites and determinants of early cleavages in the proteolytic processing pathway of reovirus surface protein sigma3.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- Strain-specific differences in reovirus infection of murine macrophages segregate with polymorphisms in viral outer-capsid protein σ3.Journal of virology · 2024Article
- A Single Point Mutation, AsnViruses · 2021Article
- The role of cysteine peptidases in coronavirus cell entry and replication: The therapeutic potential of cathepsin inhibitors.PLoS pathogens · 2020Review
- Article
- Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic PotencyJournal of virology · 2020Article
- Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.Journal of virology · 2020Article
- Selection and Characterization of a Reovirus Mutant with Increased Thermostability.Journal of virology · 2019Article
- Components of the Reovirus Capsid Differentially Contribute to Stability.Journal of virology · 2019Article
- Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.Viruses · 2015Review
- Proteolytic disassembly of viral outer capsid proteins is crucial for reovirus-mediated type-I interferon induction in both reovirus-susceptible and reovirus-refractory tumor cells.BioMed research international · 2015Article
- Cell entry-associated conformational changes in reovirus particles are controlled by host protease activity.Journal of virology · 2012Article
- Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A.PloS one · 2012Article
- Identification of a small-molecule entry inhibitor for filoviruses.Journal of virology · 2011Article
- Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry.Journal of medicinal chemistry · 2011Article
- From touchdown to transcription: the reovirus cell entry pathway.Current topics in microbiology and immunology · 2010Review
- Proteasome inhibitors enhance bacteriophage lambda (lambda) mediated gene transfer in mammalian cells.Virology · 2009Article
- The P2 capsid protein of the nonenveloped rice dwarf phytoreovirus induces membrane fusion in insect host cells.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Proteolytic disassembly is a critical determinant for reovirus oncolysis.Molecular therapy : the journal of the American Society of Gene Therapy · 2007Article
- A plasmid-based reverse genetics system for animal double-stranded RNA viruses.Cell host & microbe · 2007Article
- Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein.Journal of virology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Entry of mammalian reovirus virions into target cells requires proteolytic processing of surface protein sigma3. In the virion, sigma3 mostly covers the membrane-penetration protein mu1, appearing to keep it in an inactive form and to prevent it from interacting with the cellular membrane until the proper time in infection. The molecular mechanism by which sigma3 maintains mu1 in this inactive state and the structural changes that accompany sigma3 processing and mu1 activation, however, are not well understood. In this study we characterized the early steps in sigma3 processing and determined their effects on mu1 function and particle infectivity. We identified two regions of high protease sensitivity, "hypersensitive" regions located at residues 208 to 214 and 238 to 244, within which all proteases tested selectively cleaved sigma3 as an early step in processing. Further processing of sigma3 was required for infection, consistent with the fact that the fragments resulting from these early cleavages remained bound to the particles. Reovirus type 1 Lang (T1L), type 3 Dearing (T3D), and T1L x T3D reassortant virions differed in the sites of early sigma3 cleavage, with T1L sigma3 being cleaved mainly at residues 238 to 244 and T3D sigma3 being cleaved mainly at residues 208 to 214. These virions also differed in the rates at which the early cleavages occurred, with cleavage of T1L sigma3 occurring faster than cleavage of T3D sigma3. Analyses using chimeric and site-directed mutants of recombinant sigma3 identified carboxy-proximal residues 344, 347, and 353 as the primary determinants of these strain differences. The spatial relationships between these more carboxy-proximal residues and the hypersensitive regions were discerned from the sigma3 crystal structure. The results indicate that proteolytic processing of sigma3 during reovirus disassembly is a multistep pathway with a number of molecular determinants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.